WO2016127876A1 - 一种丙酸阿比特龙的晶型及其制备方法 - Google Patents
一种丙酸阿比特龙的晶型及其制备方法 Download PDFInfo
- Publication number
- WO2016127876A1 WO2016127876A1 PCT/CN2016/073254 CN2016073254W WO2016127876A1 WO 2016127876 A1 WO2016127876 A1 WO 2016127876A1 CN 2016073254 W CN2016073254 W CN 2016073254W WO 2016127876 A1 WO2016127876 A1 WO 2016127876A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- abiraterone
- abiraterone propionate
- propionate
- crystal form
- solvent
- Prior art date
Links
- VMXJMFCFBUTILN-MSFOBWSXSA-N CCC(O[C@@H]1CC2=CC[C@@H]([C@H]3[C@](C)(CC4)C(c5cccnc5)=CC3)[C@H]4[C@@]2(C)CC1)=O Chemical compound CCC(O[C@@H]1CC2=CC[C@@H]([C@H]3[C@](C)(CC4)C(c5cccnc5)=CC3)[C@H]4[C@@]2(C)CC1)=O VMXJMFCFBUTILN-MSFOBWSXSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- Abiraterone acetate exerts its pharmacological action by converting it into abiraterone (formula III) in vivo.
- Abiraterone is a cytochrome oxidase P450 (CYP450) c17 inhibitor that reduces androgen levels by inhibiting CYP450c17, a key enzyme in androgen synthesis. Therefore, abiraterone not only tests the testes but also other parts of the body. Androgen produced by the adrenal gland and the like have an inhibitory effect.
- CYP450 cytochrome oxidase P450
- Abiraterone propionate is a homologue of abiraterone acetate, chemical name is (3 ⁇ )-17-(3-pyridyl)-androst-5,16-dien-3-ol propionate
- the structure is as shown in Formula I.
- WO2014111815A2 discloses abiraterone propionate. Similar to abiraterone acetate, abiraterone propionate can also be converted into abiraterone in the body to exert its pharmacological effects. At present, there is no report on the crystal form of abiraterone propionate. Therefore, the study on the crystal form of abiraterone propionate is of great significance.
- the abiraterone propionate form A provided by the invention has an X-ray powder diffraction pattern having characteristic diffraction peaks at 2 ⁇ 0.2°, and the 2 ⁇ is 5.7°, 11.9°, 12.4°, 14.9°, 15.8°, 16.7°, 18.5°, 19.1°, 21.7°, 22.4°, 39.9°.
- the abiraterone propionate form A of the present invention has an X-ray powder diffraction pattern having a 2 ⁇ value of 5.3°, 5.7°, 11.9°, 12.4°, 14.2°, 14.9°, 15.8°. , 16.7°, 17.0°, 18.5°, 19.1°, 20.3°, 21.7°, 22.4°, 22.9°, 23.4°, 24.9°, 25.7°, 26.9°, 27.6°, 27.9°, 28.2°, 30.0°, 32.4
- the positions of °, 34.6°, 37.1°, 37.8°, 39.1°, and 39.9° ⁇ 0.2° correspond to diffraction peaks.
- Another object of the present invention is to provide a process for preparing abiraterone propionate Form A which comprises dissolving abiraterone propionate in a suitable organic solvent, crystallization under agitation, and separation.
- a method of preparing abiraterone propionate Form A of the present invention comprising the steps of:
- the temperature at which abiraterone propionate is dissolved in step a) is from 0 ° C to the boiling point of the solvent;
- the poor solvent in the step b) means a solvent which is poorly soluble in abiraterone propionate at room temperature and which is miscible with a solvent which dissolves abiraterone propionate.
- the method of the present invention the cooling and crystallization in the step b) and the addition of the poor solvent crystallization may be used singly or in combination.
- suitable solvents include methanol, ethanol, isopropanol, acetone, ethyl acetate, methyl acetate, dichloromethane, chloroform, acetonitrile, tetrahydrofuran, n-heptane or mixtures thereof;
- the cooling end temperature is generally 10 ° C lower than the dissolution temperature
- the cooling end temperature is lower than the dissolution temperature by 30 ° C or more;
- the cooling end temperature is lower than the dissolution temperature by 50 ° C or more;
- the poor solvent refers to a solvent which is poorly soluble at room temperature to abiraterone propionate and which is miscible with a solvent which dissolves abiraterone propionate;
- the poor solvent includes lower alkanes (such as n-hexane, petroleum ether, cyclohexane, and positive). Pentane, n-heptane, etc.), methyl tert-butyl ether, etc.;
- the feeding method may be adding a poor solvent to the abiraterone acetate solution, or adding the abiraterone acetate solution to the poor solvent;
- the cooling and crystallization and the addition of poor solvent crystallization may be used singly or in combination;
- drying temperature is 25 to 80 ° C;
- It can be dried at normal pressure or dried under reduced pressure.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the abiraterone propionate Form A of the present invention and a pharmaceutically acceptable adjuvant.
- composition of the present invention is all conventional excipients in the art, and the preparation method thereof is also a conventional method in the art, and will not be further described herein.
- the pharmaceutical composition of the present invention may be in the form of an oral preparation, an injection or an external preparation, and the like, and the oral preparation may be a tablet, a capsule, a pill, a granule, a controlled release tablet or a capsule or the like.
- These formulations may be prepared by conventional excipients and corresponding conventional methods in the art.
- the abiraterone propionate form A of the present invention is stable in physical and chemical properties and is suitable for long-term storage and manufacturing processes of its preparations.
- Figure 1 is an X-ray powder diffraction pattern of abiraterone propionate Form A.
- the X-ray powder diffraction analysis according to the present invention is a CuK ⁇ source of a Shimadzu XRD-6000 X-ray diffractometer under ambient temperature and ambient humidity. The measurement is completed.
- the "ambient temperature” is generally 0 to 40 ° C; the “ambient humidity” is generally 30% to 80% relative humidity.
- abiraterone used hereinafter can be obtained by the method disclosed in the patents GB 2265624 and WO95/09178.
- the abiraterone propionate crystal form A obtained in Examples 3-8 was subjected to X-ray powder diffraction test, and each had a characteristic peak as shown in FIG.
- the crystal forms obtained in Examples 2 to 4 were stored in an environment having a temperature of 40 ⁇ 2 ° C and a humidity of RH 75 ⁇ 5% for 3 months, and were respectively placed for 0 days, 1 month, 2 months, and 3 times. The melting point, specific rotation, purity and crystal appearance of the month were changed. The results are shown in Table 2.
Abstract
Description
2θ值(°) | d值(A) | 相对强度(%) | 2θ值(°) | d值(A) | 相对强度(%) |
5.3 | 16.61 | 4 | 5.7 | 15.57 | 73 |
11.9 | 7.43 | 29 | 12.4 | 7.15 | 15 |
14.2 | 6.25 | 4 | 14.9 | 5.96 | 57 |
15.8 | 5.62 | 25 | 16.7 | 5.30 | 11 |
17.0 | 5.20 | 4 | 18.5 | 4.79 | 100 |
19.1 | 4.64 | 53 | 20.3 | 4.34 | 3 |
21.7 | 4.09 | 52 | 22.4 | 3.96 | 44 |
22.9 | 3.88 | 6 | 23.4 | 3.80 | 5 |
24.9 | 3.57 | 8 | 25.7 | 3.46 | 7 |
26.9 | 3.30 | 21 | 27.6 | 3.23 | 3 |
27.9 | 3.19 | 4 | 28.2 | 3.16 | 6 |
30.0 | 2.97 | 3 | 32.4 | 2.76 | 3 |
34.6 | 2.59 | 3 | 37.1 | 2.42 | 4 |
37.8 | 2.38 | 4 | 39.1 | 2.30 | 3 |
39.9 | 2.26 | 17 | —— | —— | —— |
Claims (8)
- 一种丙酸阿比特龙晶型A,其特征在于,其X-射线粉末衍射图谱在2θ±0.2°处具有特征衍射峰,所述2θ为5.7°、11.9°、12.4°、14.9°、15.8°、16.7°、18.5°、19.1°、21.7°、22.4°、39.9°。
- 如权利要求1所述的晶型A,其特征在于,所述X-射线粉末衍射图谱在2θ±0.2°处具有衍射峰,所述2θ为5.3°、5.7°、11.9°、12.4°、14.2°、14.9°、15.8°、16.7°、17.0°、18.5°、19.1°、20.3°、21.7°、22.4°、22.9°、23.4°、24.9°、25.7°、26.9°、27.6°、27.9°、28.2°、30.0°、32.4°、34.6°、37.1°、37.8°、39.1°、39.9°。
- 一种制备丙酸阿比特龙晶型A的方法,其特征在于,所述方法包括如下过程:a)将丙酸阿比特龙溶于有机溶剂中;b)搅拌下,冷却析晶和/或加入不良溶剂析晶;c)分离出固体。
- 如权利要求3所述的方法,其特征在于,其所述有机溶剂为甲醇、乙醇、异丙醇、丙酮、乙酸乙酯、乙酸甲酯、二氯甲烷、三氯甲烷、乙腈、四氢呋喃或正庚烷中的一种或几种的混合物。
- 如权利要求3所述的方法,其特征在于,步骤a)中溶解丙酸阿比特龙的温度为0℃到有机溶剂沸点。
- 如权利要求3所述的方法,其特征在于,步骤b)中所述不良溶剂是指在常温下对丙酸阿比特龙溶解性不好且能与溶解丙酸阿比特龙的溶剂混溶的溶剂。
- 如权利要求3所述的方法,其特征在于,步骤c)后还包括将分离出的固体进行干燥的步骤。
- 一种药物组合物,其特征在于,包括如权利要求1或2所述的丙酸阿比特龙晶型A和药用辅料。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16748677.8A EP3257860A1 (en) | 2015-02-15 | 2016-02-03 | Crystal form of abiraterone propionate and preparation method therefor |
CA2980222A CA2980222A1 (en) | 2015-02-15 | 2016-02-03 | Crystal form of abiraterone propionate and preparation method therefor |
AU2016218748A AU2016218748A1 (en) | 2015-02-15 | 2016-02-03 | Crystal form of Abiraterone propionate and preparation method therefor 104710499A |
US15/551,185 US10087212B2 (en) | 2015-02-15 | 2016-02-03 | Crystal form of Abiraterone propionate and preparation method therefor |
JP2017542875A JP2018505206A (ja) | 2015-02-15 | 2016-02-03 | アビラテロンプロピオネートの結晶形及びその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510080991.3A CN104710499A (zh) | 2015-02-15 | 2015-02-15 | 一种丙酸阿比特龙的晶型及其制备方法 |
CN201510080991.3 | 2015-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016127876A1 true WO2016127876A1 (zh) | 2016-08-18 |
Family
ID=53410275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/073254 WO2016127876A1 (zh) | 2015-02-15 | 2016-02-03 | 一种丙酸阿比特龙的晶型及其制备方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10087212B2 (zh) |
EP (1) | EP3257860A1 (zh) |
JP (1) | JP2018505206A (zh) |
CN (1) | CN104710499A (zh) |
AU (1) | AU2016218748A1 (zh) |
CA (1) | CA2980222A1 (zh) |
WO (1) | WO2016127876A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710499A (zh) | 2015-02-15 | 2015-06-17 | 重庆医药工业研究院有限责任公司 | 一种丙酸阿比特龙的晶型及其制备方法 |
US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
JP2022523819A (ja) | 2019-03-06 | 2022-04-26 | プロペラ セラピューティクス インコーポレイテッド | アビラテロンプロドラッグ |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101768199A (zh) * | 2009-12-24 | 2010-07-07 | 深圳万乐药业有限公司 | 醋酸阿比特龙的多晶型物及其制备方法 |
WO2014111815A2 (en) * | 2013-01-18 | 2014-07-24 | Cortendo Ab (Publ) | Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction |
CN104710499A (zh) * | 2015-02-15 | 2015-06-17 | 重庆医药工业研究院有限责任公司 | 一种丙酸阿比特龙的晶型及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710498A (zh) * | 2015-02-15 | 2015-06-17 | 重庆医药工业研究院有限责任公司 | 一种丁酸阿比特龙的晶型及其制备方法 |
-
2015
- 2015-02-15 CN CN201510080991.3A patent/CN104710499A/zh active Pending
-
2016
- 2016-02-03 JP JP2017542875A patent/JP2018505206A/ja active Pending
- 2016-02-03 US US15/551,185 patent/US10087212B2/en active Active
- 2016-02-03 WO PCT/CN2016/073254 patent/WO2016127876A1/zh active Application Filing
- 2016-02-03 EP EP16748677.8A patent/EP3257860A1/en not_active Withdrawn
- 2016-02-03 AU AU2016218748A patent/AU2016218748A1/en not_active Abandoned
- 2016-02-03 CA CA2980222A patent/CA2980222A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101768199A (zh) * | 2009-12-24 | 2010-07-07 | 深圳万乐药业有限公司 | 醋酸阿比特龙的多晶型物及其制备方法 |
WO2014111815A2 (en) * | 2013-01-18 | 2014-07-24 | Cortendo Ab (Publ) | Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction |
CN104710499A (zh) * | 2015-02-15 | 2015-06-17 | 重庆医药工业研究院有限责任公司 | 一种丙酸阿比特龙的晶型及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2980222A1 (en) | 2016-08-18 |
EP3257860A1 (en) | 2017-12-20 |
US20180030085A1 (en) | 2018-02-01 |
CN104710499A (zh) | 2015-06-17 |
AU2016218748A1 (en) | 2017-10-05 |
US10087212B2 (en) | 2018-10-02 |
JP2018505206A (ja) | 2018-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3702351B1 (en) | Formulation comprising a mek inhibitor | |
BRPI0608689A2 (pt) | composto, composiÇço, processos para preparar monoidrato e a forma de cristal, e, uso de um monoidrato ou de uma forma de cristal | |
WO2010083752A1 (zh) | 一种高纯度的非布司他及其制备方法 | |
WO2017107972A1 (zh) | 一种选择性s1p1受体激动剂的新晶型及其制备方法 | |
WO2016127876A1 (zh) | 一种丙酸阿比特龙的晶型及其制备方法 | |
WO2018184185A1 (zh) | 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 | |
WO2015014315A1 (zh) | 一种抑制剂的晶型及其制备方法和用途 | |
EP2603509B1 (en) | Crystalline form of pyrimido[6,1-a] isoquinolin-4-one compound | |
WO2016169422A1 (zh) | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 | |
WO2016058472A1 (zh) | 维生素d2与d3的共晶及其制备方法和用途 | |
HUE033085T2 (en) | A method of producing solid abiraterone acetate | |
WO2019153644A1 (zh) | 盐酸去亚甲基小檗碱晶型及其制备方法 | |
TWI740922B (zh) | 一種奧貝膽酸的新結晶形式及其製備方法 | |
CN111171009B (zh) | 恩曲替尼晶型及其制备方法 | |
WO2016188444A1 (zh) | 一种尿酸转运蛋白抑制剂的钠盐及其结晶形式 | |
TWI705065B (zh) | 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途 | |
WO2018214877A1 (zh) | 一种地佐辛晶型及其制备方法 | |
JP6400580B2 (ja) | 3−ホルミルリファマイシンsv及び3−ホルミルリファマイシンsの3−(4−シンナミル−1−ピペラジニル)アミノ誘導体を含有する医薬製剤並びにこれらの製造方法 | |
WO2016197980A1 (zh) | 一种黄芩苷a晶型、其制备方法及其应用 | |
WO2013013594A1 (zh) | 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的无定形物及其制备方法 | |
CN104710498A (zh) | 一种丁酸阿比特龙的晶型及其制备方法 | |
US7795435B2 (en) | Process for obtaining the polymorphic form I of finasteride | |
WO2022194160A1 (zh) | 非索替尼固体形式及其制备方法 | |
CN114940695B (zh) | 一种具有抗肿瘤活性的雄诺龙衍生物及其制备方法与应用 | |
WO2022166774A1 (zh) | 3-羟基-5-孕烷-20-酮衍生物的晶型及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16748677 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017542875 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15551185 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2016748677 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2980222 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016218748 Country of ref document: AU Date of ref document: 20160203 Kind code of ref document: A |